Todd M. DuChene, Chief Legal and Administrative Officer at Core Scientific, Inc., executed a sale of 10,000 shares of the company's common stock on April 1, 2026, realizing proceeds of $152,523. The sale was carried out at a weighted average price of $15.2523 per share, with individual execution prices spanning from $14.98 to $15.50.
The transactions around the start of April followed a material grant and related vesting activity on March 31, 2026. On that date DuChene received 216,734 shares of Core Scientific common stock as part of a performance-based restricted stock unit grant; those granted shares were recorded with a value of $0 for accounting purposes tied to the performance criteria. Concurrent with the vesting, 97,652 shares were withheld to satisfy tax obligations, with the withholding calculated at a price of $14.96 per share and totaling $1,460,873.
After completing the April 1 sale and accounting for the March 31 vesting and withholding, DuChene's direct holding in Core Scientific stands at 2,047,089 shares.
The insider sale was reported under a pre-arranged Rule 10b5-1 trading plan that DuChene adopted on December 5, 2025.
Separately from executive-level transactions, Core Scientific has bolstered its liquidity profile through an additional $500 million credit facility provided by JPMorgan Chase Bank, bringing the company's total funded commitments to $1 billion. This new facility follows a prior $500 million loan from Morgan Stanley. Both facilities share similar economic and term features: a 364-day maturity and an interest rate tied to the Secured Overnight Financing Rate plus 250 basis points.
Market participants and analysts have responded to the company's financing moves and operational developments. One analysis cited in company materials indicates the stock has returned 127% over the past 12 months but is trading above a stated Fair Value estimate. The firm's reported volatility is notable, with a beta of 6.9 highlighted as an indicator of extreme price swings.
Broker and research activity around Core Scientific has been active in recent coverage. Citizens reiterated a Market Outperform rating and maintained a $30.00 price target even after adjusting estimates to reflect lower near-term contributions from bitcoin mining. Canaccord lifted its price target from $17 to $20, pointing to the company’s acquisition of a new site in Texas and expanded power capacity at its Dalton, Georgia, and Pecos, Texas facilities. Needham upgraded the stock to Buy from Hold and set a $23.00 price target, citing attractive valuation metrics and the potential for a new lease agreement in the near future.
These financing arrangements, analyst updates and asset expansions underline Core Scientific's ongoing efforts to manage liquidity and grow operational capacity amid variable near-term production from bitcoin mining. The company’s mix of newly secured short-term financing and upgrades or revisions in analyst coverage frames the current investor discussion around both funding flexibility and the timing of mining contributions to revenue.